EUCTR2011-002119-27-SK进行中（未招募）不适用
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TOCOMPARE THE EFFICACY AND SAFETY OF INTRAVENOUS CXA-201 WITH THAT OF MEROPENEM IN COMPLICATED INTRAABDOMINAL INFECTIONS
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 780
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provide written informed consent prior to any study-related procedure not part of normal medical care (2. Be males or females = 18 years of age.
- •3. If female, subject is non-lactating, and is either:
- •a. Not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy, or hysterectomy; or
- •b. Of childbearing potential and is practicing a barrier method of birth control (e.g., a diaphragm or contraceptive sponge) along with 1 of the following methods: oral or parenteral contraceptives (for 3 months prior to study drug administration), or a vasectomized partner. Or practice these methods for the duration of the trial and for at least 35 days after last dose of study medication.
- •4. Males are required to practice reliable birth control methods (condom or other barrier device) during the conduct of the study and for at least 35 days after last dose of study medication.
- •5. One of the following diagnoses (in which there is evidence of intraperitoneal infection) including:
- •a. Cholecystitis (including gangrenous cholecystitis) with rupture, perforation, or progression of the infection beyond the gallbladder wall;
- •b. Diverticular disease with perforation or abscess;
- •c. Appendiceal perforation or periappendiceal abscess;
- •d. Acute gastric or duodenal perforation, only if operated on > 24 hours after perforation occurs;
- •e. Traumatic perforation of the intestine, only if operated on > 12 hours after perforation occurs;
- •f. Peritonitis due to other perforated viscus or following a prior operative procedure;
- •i. Subjects with inflammatory bowel disease or ischemic bowel disease are eligible provided there is bowel perforation.
- •g. Intraabdominal abscess (including liver or spleen).
- •6. Subject requires surgical intervention (e.g., laparotomy, laparoscopic surgery, or percutaneous draining of an abscess) within 24 hours of (before or after) the first dose of study drug.
- •7. If subject is to be enrolled preoperatively, the subject should have radiographic evidence of bowel perforation or intraabdominal abscess.
- •8. Subjects who failed prior antibacterial treatment for the current cIAI can be enrolled but must: (a) have a positive culture (from an intraabdominal site) and (b) require surgical intervention. Such
- •subjects can be enrolled before the results of the culture are known; however, if the culture is negative, study drug administration must be discontinued.
- •9. Willing and able to comply with all study procedures and restrictions.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 585
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 195
排除标准
- •1. Diagnosis of abdominal wall abscess; small bowel obstruction or ischemic bowel disease without perforation.
- •2. Simple appendicitis; acute suppurative cholangitis; infected necrotizing pancreatitis; pancreatic abscess; or pelvic infections.
- •3. Spontaneous [primary] bacterial peritonitis associated with cirrhosis and chronic ascites.
- •4. Complicated intraabdominal infection managed by staged abdominal repair (STAR), open abdomen technique including temporary closure of the abdomen, or any situation where infection source control is not likely to be achieved.
- •5. Known prior to randomization to have an IAI or postoperative infection caused by pathogen(s) resistant to meropenem.
- •6. Use of systemic antibiotic therapy for IAI for more than 24 hours prior to the first dose of study drug, unless there is a documented treatment failure with such therapy.
- •7. More than one dose of an active non-study antibacterial regimen given postoperatively. For subjects enrolled preoperatively, no postoperative non-study antibacterial therapy is allowed.
- •8. Subjects who previously received imipenem, meropenem, doripenem or cefepime for the current intraabdominal infection.
- •9. Have a concomitant infection at the time of randomization, which requires non-study systemic antibacterial therapy in addition to IV study drug therapy. (Drugs with only gram-positive activity [e.g., daptomycin, vancomycin, linezolid] are allowed).
- •10. Severe impairment of renal function (estimated creatinine clearance [CrCl] < 30 mL/min), or requirement for peritoneal dialysis, hemodialysis or hemofiltration, or oliguria (< 20 mL/h urine output over 24 hours).
- •11. The presence of hepatic disease at baseline as defined by any of the following:
- •a. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 4 x upper limit of normal (ULN)
- •b. Total bilirubin > 2 x ULN, unrelated to cholecystitis
- •c. Alkaline phosphatase > 4 x ULN. Subjects with a value > 4 x ULN and < 5 x ULN are eligible if this value is historically stable
- •d. Acute or chronic hepatitis, cirrhosis, acute hepatic failure, acute decompensation of chronic hepatic failure.
- •12. Hematocrit < 25% or hemoglobin < 8 gm/dL.
- •13. Neutropenia with absolute neutrophil count < 1000 /mm3.
- •14. Platelet count < 75,000 /mm3. Subjects with a platelet count as low as 50,000 /mm3 are permitted if the reduction is historically stable.
- •15. Considered unlikely to survive the 4- to 5-week study period.
- •16. Any rapidly-progressing disease or immediately life-threatening illness (including respiratory failure and septic shock).
- •17. Immunocompromising condition, including established Acquired Immune Deficiency Syndrome (AIDS), hematological malignancy, or bone marrow transplantation, or immunosuppressive therapy including cancer chemotherapy, medications for prevention of organ transplantation rejection, or the administration of corticosteroids equivalent to or greater than 40 mg of prednisone per day administered continuously for more than 14 days preceding randomization.
- •18. Have a documented history of any moderate or severe hypersensitivity or allergic reaction to any ß-lactam antibacterial (a history of a mild rash followed by uneventful re-exposure is not a
- •contraindication to enrollment), including cephalosporins, carbapenems, penicillins, or ß-lactamase inhibitors, or metronidazole, or nitroimidazole derivatives.
- •19. Any condition or circumstance that, in the opinion of the Investigator, would compromise the saf
研究者
相似试验
进行中（未招募）
不适用
A trial to test a new antibiotic given by vein to be used for ComplicatedUrinary Tract infections by comparing it to a well known antibiotic,levofloxacin.Complicated Urinary Tract Infection, Including PyelonephritisMedDRA version: 14.1Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-023452-87-DECubist Pharmaceuticals, Inc.776
进行中（未招募）
不适用
A trial to test a new antibiotic given by vein to be used for complicatedintraabdominal infectionsComplicated Intra abdominal InfectionsMedDRA version: 14.1Level: LLTClassification code 10056570Term: Intra-abdominal infectionSystem Organ Class: 100000004862EUCTR2011-002120-41-DECubist Pharmaceuticals, Inc.500
进行中（未招募）
1 期
A trial to test a new antibiotic given by vein to be used for Complicated Urinary Tract infections by comparing it to a well known antibiotic, levofloxacin.Complicated Urinary Tract Infection, Including PyelonephritisMedDRA version: 17.1 Level: HLT Classification code 10046577 Term: Urinary tract infections System Organ Class: 100000004862EUCTR2010-023452-87-ROCubist Pharmaceuticals, Inc.1,083
进行中（未招募）
不适用
A trial to test a new antibiotic given by vein to be used for ComplicatedUrinary Tract infections by comparing it to a well known antibiotic,levofloxacin.Complicated Urinary Tract Infection, Including PyelonephritisMedDRA version: 14.1Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 100000004862EUCTR2010-023453-11-SICubist Pharmaceuticals, Inc.500
进行中（未招募）
不适用
A trial to test a new antibiotic given by vein to be used for Complicated Urinary Tract infections by comparing it to a well known antibiotic, levofloxacin.Complicated Urinary Tract Infection, Including PyelonephritisMedDRA version: 16.0Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 100000004862EUCTR2010-023452-87-SKCubist Pharmaceuticals, Inc.500